OR WAIT null SECS
Check out the latest features and columns!
Supply chain issues, psychedelic medicines, immunotherapies, social engagement, telemedicine, access barriers, corporate branding, and the rise of Chinese biotech are industry topics that deserve a closer look as we head into the future
January's Executive Profile features CEO of Sumitovant Biopharma, Myrtle Potter
Pharm Exec's 17th Annual Pipeline Report focuses on Alzheimer’s disease, ophthalmology, NASH, anti-infectives, and opioids
These five brands prove that pharma marketers can pull it together with compelling stories, and meaningful patient impact, even during a pandemic
Chief commercial officers gather for an insightful roundtable discussion anchored in the future of sales and marketing in light of new communication media brought on by the pandemic
How can clinical trials be designed to best study therapies for treating long COVID?
Highlighted Videos
January 14, 2022
Pharma R&D return on investment rises to highest level since 2014.
Award-winning omnichannel education platform for life sciences expands executive team to support strategic growth.
January 13, 2022
DeepIntent’s patient-modeled audiences solution uses comprehensive real-world clinical datasets to precisely reach patient populations, including those facing rare diseases and low prevalence conditions.
Cernese shares his perspectives on the increasing demand for quick, accessible health information, the subsequent pressure this puts on the highly regulated life sciences industry, and how artificial intelligence (AI), the use of machine learning to perform tasks that traditionally rely on human intelligence, can help.
As emerging technologies are identified, C-suites need to determine how they might be pragmatically deployed as solutions to address their pain points, says IBM‘s Dr. Bernard S. Meyerson.
January 12, 2022
Biopharma must step up amidst growing oncology market.
Ashfield Engage and ysura announce partnership to transform HCP and pharma interactions through a superior customer experience
In a highly unusual decision for a therapy approved by FDA, CMS has taken action to limit prescribing and use of Biogen’s new and controversial Alzheimer’s treatment Aduhelm.
